Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score)

Tree-structured risk stratification of in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction: A report from the New York State percutaneous coronary intervention database

“…In many ways our analysis confirms not only the importance but also the ordering of clinical factors that have been repeatedly demonstrated as strong predictors of outcome following AMI [26][27][28]. Not surprisingly, patients with cardiogenic shock were identified as the highest risk group followed by those with congestive heart failure.…”

“…These risk factors were identified even in the earliest of risk stratification schemes, the Killip classification [29]. Besides the primary angioplasty in myocardial infarction (PAMI) risk score that excludes cardiogenic shock patients [26], perhaps our model is the only other risk model that doesn't require angiographic variables prior to risk stratification. Therefore, potential application of our model includes the efficient and early identification of high-risk groups in whom not only therapy may be tailored to risk, but also allow a frank discussion of risks and benefits of potential treatment strategies such as cardiac catheterization.…”

International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee

“…These clinical and demographic factors have been recognized as important risk factors among patients with MI in clinical guidelines 29. Moreover, these risk factors are incorporated in a number of risk prediction models for patients with MI 6, 7, 28, 30, 31, 32, 33, 34…”

Can we improve length of hospitalization in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention?

“…Numerous bedside tools have been developed to stratify patients with STEMI to identify a low-risk group of patients who are unlikely to experience complications above the background rate and who can be discharged from the hospital after a brief period of observation. The Zwolle primary PCI index (4) [7] and TIMI-STEMI [8]) and clearly identifies a majority of patients who can be discharged early. Although a more comprehensive score in the setting of primary PCI has since been reported (ie, the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications [CADILLAC] [9] score), we found that the Zwolle score was practical as a clinical bedside tool, with the ability to discriminate between high-and low-risk patients.…”